Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1. A late event occurred in 2.9% of 5-year event-free survivors supporting guidelines to limit surveillance for these events to 5 years from diagnosis.
Authors
- Susan M. Hiniker (ORCID: https://orcid.org/0000-0003-4723-2151)
- Archana Shenoy (ORCID: https://orcid.org/0000-0003-0733-5260)
- Amira Qumseya
- Sara Kreimer (ORCID: https://orcid.org/0000-0002-9817-381X)
- Dana L. Casey (ORCID: https://orcid.org/0000-0001-6851-7653)
- Rajkumar Venkatramani (ORCID: https://orcid.org/0000-0002-4785-106X)
- Timothy B. Lautz (ORCID: https://orcid.org/0000-0002-3323-6509)
- Wei Xue
- Carola Arndt
Institutions
- University of North Carolina at Chapel Hill (US)
- Lurie Children's Hospital (US)
- Nationwide Children's Hospital (US)
- Children's Hospital of Los Angeles (US)
- Baylor College of Medicine (US)
- University of Florida (US)
- Children's Cancer Center (US)
- The Ohio State University (US)
- Stanford University (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1002/pbc.31421
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- St. Baldrick's Foundation
- National Institutes of Health